H.C. Wainwright analyst Douglas Tsao reiterated a Buy rating on Cabaletta Bio (CABA – Research Report) on May 19 and set a price target of $11.00. The company's shares closed last Friday at $1.42, close to its 52-week low of $1.17. According to TipRanks.com, Tsao is a 2-star analyst with an average return of 0.1% and a 39.2% success rate. Tsao covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co, Cerevel Therapeutics Holdings, and Praxis Precision Medicines. Currently, the analyst consensus on Cabaletta Bio is a Strong Buy with an average price target of $15.33, representing an 829.1% upside.
https://www.tipranks.com/news/blurbs/h-c-wainwright-thinks-cabaletta-bios-stock-is-going-to-recover-4?utm_source=advfn.com&utm_medium=referral